Unformatted text preview: ver (CDC 23). The next thing to do is isolate the patient from other patients who may get sick and health care workers who are not directly involved with the patient's care. The patient should be given intravenous support, as he or she is probably dehydrated from losing fluids through vomiting and diarrhea. Finally, if the patient expires, the body should be properly disposed of, preferably through cremation, so that the dead body will not spread disease to other people (CDC 26). http://www.crystalinks.com/ebola.html Treatment Medical Care: • Presently, no specific therapy is available that has demonstrated efficacy in the treatment of Ebola hemorrhagic fever. o Ribavirin, an antiviral drug previously used in other types of viral hemorrhagic fever, has no demonstrable anti-Ebola activity in vitro and has failed to protect Ebola-infected primates. o During the 1995 outbreak in Kikwit, DRC, human convalescent plasma was used to treat 8 patients with proven Ebola disease. Only 1 of these patients died. o Human recombinant interferon alpha-2b used in conjunction with hyperimmune equine IgG delayed but did not prevent death in Ebolainfected cynomolgus macaques. o Four laboratory workers in Russia who had possible Ebola exposure were treated with a combination of a goat-derived anti-Ebola immunoglobulin plus recombinant human alpha-2 interferon. One of these patients had a high-risk exposure and developed clinical evidence of Ebola infection. All 4 patients recovered. Equine IgG containing high-titer neutralizing antibodies to Ebola protected guinea pigs and baboons but was not effective in protecting infected rhesus monkeys. • Supportive therapy with attention to intravascular volume, electrolytes, nutrition, and comfort care is of benefit to the patient. Such care must be administered with strict attention to barrier isolation. All body fluids (blood, saliva, urine, stool) contain infectious virions and should be handled with great care. o Patients who have died of Ebola should be buried promptly and with as little contact as possible. • Experimental therapies are being investigated. o DNA vaccines expressing either envelope GP or nucleocapsid protein (NP) genes of Ebola virus have been demonstrated to induce protection in adult mice exposed to Ebola virus. These vaccines were administered by coating gold beads with DNA expressing the genes for either GP or NP, and they were delivered by skin particle bombardment using a Po...
View Full Document
- Spring '09
- Ebola virus, Viral hemorrhagic fever, Ebola Hemorrhagic fever, Ebola HF